The mutational landscape in MPN is highly heterogenous as approximately 55% of patients harbor the Janus kinase 2 (JAK2)V617F mutation (2), and 20% of patients a mutation in exon 9 of the calreticulin (CALR) gene (3, 4). Here, JAK2 is linked to myeloproliferative neoplasm.